Page last updated: 2024-11-04

tegafur and Stevens-Johnson Syndrome

tegafur has been researched along with Stevens-Johnson Syndrome in 3 studies

Stevens-Johnson Syndrome: Rare cutaneous eruption characterized by extensive KERATINOCYTE apoptosis resulting in skin detachment with mucosal involvement. It is often provoked by the use of drugs (e.g., antibiotics and anticonvulsants) or associated with PNEUMONIA, MYCOPLASMA. It is considered a continuum of Toxic Epidermal Necrolysis.

Research Excerpts

ExcerptRelevanceReference
"TS-1 has been used for the treatment of gastric cancer, both in the adjuvant and metastatic setting, and is increasingly being used in other malignancies such as colon, pancreatic and non-small cell lung cancer."1.37Toxic epidermal necrolysis associated with TS-1 in a patient with gastric cancer. ( Aw, CW; Lee, SC; Lim, R; Lim, TC; Tan, CS; Yeo, SW, 2011)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Komatsu-Fujii, T1
Ogawa, M1
Nonoyama, S1
Fukumoto, T1
Tanabe, H1
Tan, CS1
Lim, R1
Lim, TC1
Aw, CW1
Yeo, SW1
Lee, SC1
Yamazaki, Y1
Yamada, A1
Sugaya, S1
Osawa, A1

Other Studies

3 other studies available for tegafur and Stevens-Johnson Syndrome

ArticleYear
Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1®) after nivolumab discontinuation.
    European journal of dermatology : EJD, 2021, Feb-01, Volume: 31, Issue:1

    Topics: Aged; Antineoplastic Agents, Immunological; Drug Combinations; Female; Humans; Nivolumab; Oxonic Aci

2021
Toxic epidermal necrolysis associated with TS-1 in a patient with gastric cancer.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:5

    Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Diagnosis, Differential; Drug Combinations;

2011
[Visual disturbance].
    Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 6

    Topics: Antimetabolites, Antineoplastic; Antitubercular Agents; Cataract; Central Serous Chorioretinopathy;

2012